Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BIOCLINICA INC (BIOC)
|
Add to portfolio |
|
|
|
| Price: |
$1.26
| | Metrics |
| OS: |
15.7
|
M
| |
6
|
% ROE
|
| Market cap: |
$19.8
|
M
| |
18
|
% ROIC
|
|
Net cash:
|
$8.79
|
M
| |
$0.56
|
per share
|
|
EV:
|
$11
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$12.9
|
M
| |
0.8
|
x EV/EBITDA
|
|
EBIT
|
$7.7
|
M
| |
1.4
|
x EV/EBIT
|
| EPS |
$0.23
| |
5.6
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 98.3 | 84.0 | 75.2 | 72.7 | 69.1 | 47.3 | 40.3 | 30.5 |
| Revenue growth | 17.0% | 11.7% | 3.4% | 5.2% | 46.3% | 17.4% | 32.1% | 2.7% |
| Cost of goods sold | 67.9 | 58.2 | 52.0 | 51.0 | 32.4 | 21.9 | 19.6 | 18.3 |
| Gross profit | 30.4 | 25.8 | 23.2 | 21.8 | 36.7 | 25.4 | 20.6 | 12.2 |
| Gross margin | 30.9% | 30.7% | 30.8% | 29.9% | 53.1% | 53.7% | 51.2% | 39.9% |
| Sales and marketing | 10.7 | 8.7 | 9.0 | 8.1 | 7.9 | 5.0 | 4.3 | 4.8 |
| General and administrative | 11.6 | 10.2 | 8.4 | 7.4 | 7.0 | 5.7 | 5.1 | 5.0 |
| EBITA | 8.1 | 6.9 | 5.7 | 5.8 | 8.5 | 0.5 | 0.1 | -4.3 |
| EBITA margin | 8.2% | 8.2% | 7.6% | 8.0% | 12.3% | 1.1% | 0.4% | -14.2% |
| Amortization of intangibles | 0.5 | 0.6 | 0.6 | | | | | |
| EBIT | 7.5 | 6.3 | 5.1 | 5.8 | 8.5 | 0.5 | 0.1 | -4.3 |
| EBIT margin | 7.7% | 7.4% | 6.7% | 8.0% | 12.3% | 1.1% | 0.4% | -14.2% |
| Pre-tax income | 6.4 | 4.3 | 4.3 | 4.7 | 8.9 | 1.2 | 0.8 | -4.3 |
| Income taxes | 2.7 | 1.5 | 1.6 | 1.8 | 3.1 | -2.1 | -1.2 | -1.7 |
| Tax rate | 41.8% | 35.4% | 36.4% | 37.3% | 34.9% | | | 40.1% |
| Earnings from continuing ops | 3.7 | 2.8 | 2.8 | 3.0 | 5.8 | 3.3 | 2.0 | -2.5 |
| Earnings from discontinued ops | | | | | -3.0 | -1.0 | -1.0 | |
| Net income | 3.7 | 2.8 | 2.8 | 3.0 | 2.8 | 2.3 | 1.0 | -2.5 |
| Net margin | 3.8% | 3.3% | 3.7% | 4.1% | 4.0% | 4.9% | 2.5% | -8.3% |
| |
| Diluted EPS | $0.23 | $0.17 | $0.17 | $0.20 | $0.40 | $0.26 | $0.16 | ($0.23) |
| Shares outstanding (diluted) | 16.5 | 16.4 | 15.9 | 15.1 | 14.5 | 12.7 | 12.4 | 11.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|